Case Report

Fibrotic interstitial lung disease occurring as sequela of COVID-19 pneumonia despite concomitant steroids

Zarir Farokh Udwadia¹, Priyanka Kisan Pokhariyal², Awatansh Kumar Rajkumar Tripathi³, Anirudh Kohli⁴

¹P.D. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; ²Department of Internal Medicine, Breach Candy Hospital Trust, Mumbai, Maharashtra, India; ³Department of Pulmonary Medicine, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India; ⁴Department of Radio Diagnosis, Breach Candy Hospital Trust, Mumbai, Maharashtra, India

ABSTRACT

A 75-year-old female with no history of lung disease developed severe pulmonary fibrosis within 1 month of acute severe COVID-19 pneumonia. She developed dry basal crackles, hypoxia needing home oxygen, and computed tomography changes which dramatically evolved from acute ground-glass opacities to honeycombing and traction bronchiectasis. Interestingly, these changes occurred despite her being on steroids through most of her hospital stay. She is being commenced on pirfenidone and her responses are carefully monitored, but the role of antifibrotic drugs are unclear and will only be established from large clinical trials.

KEY WORDS: Antifibrotics, COVID-19 sequelae, pulmonary fibrosis (interstitial lung disease), SARS-CoV-2

INTRODUCTION

About 24 million people have already been affected by SARS-CoV-2 in the course of this pandemic. While the vast majority have mild infections, about 15% will develop a severe COVID-19 pneumonia, and 5% will develop ARDS, leaving almost 4.8 million with significant pulmonary involvement. While most of these will resolve without lung damage, it is likely that a significant number of patients will be left with residual sequelaes.¹

This case describes a patient with acute COVID pneumonia who, within thirty days, was left with severe fibrotic sequelae. Interestingly, this transformation from ground-glass opacities (GGO) to well-established fibrosis occurred despite her being on steroids.

CASE REPORT

A 75-year-old diabetic female was admitted with a 5-day history of fever, cough, and worsening dyspnea. There was no background of pulmonary problems and her effort tolerance was so good that she could walk 5 km daily in the week prior to admission. Her real-time polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive and her initial computed tomography (CT) on admission showed a pattern of bilateral, diffuse, peripheral GGOs, typical of acute COVID-19 pneumonia [Figure 1].

She remained extremely tachypnoeic and hypoxic despite high-flow nasal oxygen (PaO₂ 60 mmHg despite 15 L/min of

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Access this article online

Quick Response Code: www.lungindia.com

DOI: 10.4103/lungindia.lungindia_533_20

How to cite this article: Udwadia ZF, Pokhariyal PK, Tripathi AK, Kohli A. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India 2021;38:S61-3.

© 2020 Indian Chest Society | Published by Wolters Kluwer - Medknow
oxygen) and on the 5th day of her illness, needed intubation and ventilation with a lung protective ventilator strategy, her FiO₂ never exceeding 50%. She could be weaned and extubated within a week. During the 3rd week of her intensive care unit stay, she was diagnosed to have a cytokine storm, with a peak interleukin-6 of 216 pg/ml and a ferritin level of 1422 ng/ml. She was administered one dose of 400 mg of tocilizumab, and intravenous methyl prednisolone at a dose of 120 mg daily tapered gradually, seemed to initially respond.

Despite negative RT-PCRs, she continued to have persistent unexplained hypoxia, requiring supplemental nasal oxygen of 4–5 L/min. This was initially felt to be secondary to pulmonary thromboembolism, but a normal CT pulmonary angiography ruled this out. On the 30th day of her illness, a repeat high-resolution CT scan showed that she had developed well-marked fibrotic interstitial lung disease (ILD), with extensive areas of subpleural and peribronchovascular septal thickening, traction bronchiectasis, and honeycombing in both lung fields [Figure 2]. These were fresh changes, not seen in her earlier scan, and represented evolution of her earlier GGOs to fibrotic ILD. Several attempts at bedside pulmonary function test (PFT) were made, but she was too breathless to perform a forced vital capacity maneuver. Steroids were continued, pirfenidone added, and she was eventually discharged after 40 days, needing 2 L/min oxygen via a concentrator. The course of her disease is summarized in Figure 3.

**DISCUSSION**

While most patients with viral pneumonia will heal with minimal sequelae, this case documents a patient with COVID-19 pneumonia who in a timeframe of around a month developed pulmonary fibrosis with honeycombing and traction bronchiectasis. More worryingly, she developed these changes despite being on good doses of steroid for most of her hospital stay.

Fibrosis is not common following other viral pneumonias and has almost never been reported after H1N1 pneumonia. Fibrotic changes have been reported, however, in about 8% of patients with SARS and 20% of patients with H7N9 influenza.[2] Our case report suggests that residual fibrosis is possible post-COVID-19, and significant numbers of patients are likely to recover from acute COVID-19 pneumonia only to be left with severe pulmonary fibrosis as a sequelae.

The role of antifibrotic drugs such as pirfenidone and nintedanib in the setting of post-COVID fibrosis is unclear at present. They have been shown to be useful in not just idiopathic pulmonary fibrosis (IPF),[3,4] but also in a range of progressive non-IPF fibrotic ILDs.[5] There is some therapeutic rationale for the use of antifibrotics in this setting as these drugs have been shown to be useful in acute exacerbations of IPF which are often triggered by viral infections.[6] A trial with pirfenidone is already underway in China and other trials of antifibrotics in this setting are likely to commence.[7] We feel a strong case can be made for trying them in post-COVID fibrosis and commenced our patient on pirfenidone and have planned serial CT scans and PFT.

**CONCLUSION**

Even though the vast majority of COVID-19 patients will resolve completely or with minimal changes, a minority, like the patient discussed, will be left with established fibrosis. If even a few of the 24 million patients affected to date globally develop fibrosis, we are likely to see significant numbers (possibly hundreds of thousands) of patients with post-COVID fibrosis. The pulmonary...
community will need to anticipate and prepare for this potential onslaught of patients with advanced fibrotic lung disease and potential oxygen dependence.

Steroids did not seem to prevent the development of fibrosis in this patient who developed traction bronchiectasis and honeycombing despite being on steroids for most of her hospital stay. Further trials to establish the role of anti-fibrotic drugs such as pirfenidone and nintedanib in both preventing fibrosis and controlling the progression of established fibrosis are urgently needed.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis. 2020; doi:10.1016/S1473-3099(20)30434-5.
2. Chang YC, Yu CJ, Chang SC, Galvin JR, Liu HM, Hsiao CH, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: Evaluation with thin-section CT. Radiology 2005;236:1067‑75.
3. Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. Engl J Med 2014;370:2071‑82. Available from: https://pubmed.ncbi.nlm.nih.gov/24836310/. [Last accessed on 2020 Jun 24].
4. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glasspoole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083‑92. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1402582. [Last accessed on 2020 Jun 24].
5. Flaherty KR, Wells AU, Cotin V, Devaraj A, Walsh SL, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718‑27. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1908681. [Last accessed on 2020 Jun 24].
6. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med 2020;8:807‑15.
7. A Study to Evaluate the Efficacy and Safety of Pirfenidone with Novel Coronavirus Infection-Full Text View-ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04282902. [Last accessed on 2020 Jun 17].